Novavax Announces Leadership Change
October 13 2017 - 7:30AM
Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. “Buck”
Phillips has submitted his resignation as Senior Vice President,
Chief Financial Officer (CFO) and Treasurer, to pursue an expanded
opportunity in the industry. Mr. Phillips will step down effective
November 10, 2017, and will provide financial, accounting and
transition services as a consultant to Novavax until December 31,
2017. Mr. Erck will act as the interim CFO pending completion of a
search for a new Chief Financial Officer.
“Buck has been instrumental in a number of
significant Novavax accomplishments, and we thank him for all his
contributions over the last four years. We wish him all the best in
his new endeavors,” said Stanley C. Erck, President and CEO of
Novavax.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biotechnology company committed to delivering novel products to
prevent a broad range of infectious diseases. Our recombinant
nanoparticles and Matrix-M™ adjuvant technology are the foundation
for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax
is available on the Company's website, novavax.com.
Contact:
Investor RelationsNovavax, Inc.Andrea N. Flynn, Ph.D.Director,
Investor & Media Relationsir@novavax.com240-268-2000
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024